MENU menu

FAQS: In-Vitro Diagnostic Medical Device Regulation (IVDR)


Along with the EU Regulation on medical devices (MDR), the EU Regulation 2017/746 of the European Parliament and of the Council on in-vitro diagnostic medical devices (IVDR) entered into force on 26 May 2017. After a 5 year transition period, the IVDR will replace the EU’s current Directive on in-vitro diagnostic medical devices (98/79/EC).

Discover quick facts about the expected changes below.


The IVDR is the new regulatory basis for placing on the market, making available and putting into service in-vitro diagnostic medical devices on the European market. It will replace the EU’s current Directive on in-vitro diagnostic medical devices (98/79/EC). As a European regulation, it will be effective in all EU member states and EFTA states immediately without need to be transferred into the law of respective states, however national laws may be adapted to back up some requirements in more detail.


The IVDR came into force on 25 May 2017. Several implementing acts/guidance documents are being issued by the EU Commission and are stipulated to complete some of the requirements to be met. The 5 year transition period to give companies time to comply with the new regulation ends on 25 May 2022.


Some of the key changes of the IVDR include:


From 26 May 2022 all in-vitro diagnostic medical devices must meet the requirements of the IVDR in order to be placed in the European market. Products already certified by a Notified Body may be placed on the market until 25 May 2024 under some conditions and if the manufacturer fulfils the specific prerequisite requirements drawn in the IVDR (Article 110 (3)).



“Placing on the market” implies that the device is manufactured and sold by the Manufacturer or Importer to a different legal entity although not necessarily physically transferred. Any subsequent operation, for example, from a distributor to an end-user is defined as making available. Both placing on the market and making available on the market refer to each individual device, not to a type of device, and whether it was manufactured as an individual unit or in series.


Consequently, even though a device model or type has been supplied before the IVDR Date of Application, individual units of the same model or type, which are placed on the market after the Date of Application, must comply with the IVDR requirements.




The IVDR introduced many changes to the regulatory requirements for IVDs in the EU as explained in question 4 above.


These changes will require significant investment (time, resources, budget) from Manufacturers to meet the new requirements.  In addition, guidance documents, implementing and delegated acts are still to be published. Manufacturers of in-vitro diagnostic medical devices are strongly advised to stay current on amendments to IVDR and work with their Notified Body to ensure a timely review and approval of their devices ahead of the IVDR Date of Application.


The Regulation on in-vitro diagnostic medical devices (IVD) has many common aspects and requirements to the Regulation on medical devices but system changes and other IVD specific changes will have important implications and changes for that product sector. These include, but are not limited to:


Not sure how does your IVD classify under IVDR?

Looking for more support on In-Vitro Diagnostic Regulations?

Contact our Experts!


Send us an email at

Med-Di-Dia - Your Regulatory Risk Partner for Medical Devices, Diagnostics and Digital Health!







Get access to the Med-Di-Dia’s newsletter, where industry experts help you to stay on top of shifting global markets.

Stay updated with the latest Trends in the world of Medical Devices!


* indicates required